Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

Short-acting RA: Provides shorter GLP-1 receptor activation. The effects last only for a few hours. Examples include ...

Glucagon-like peptide medications that treat Type 2 diabetes and weight management continue to grow in popularity, though ...

It can be harder to lose weight after a certain age, which is why GLP-1 medications can be incredibly useful. That's where ...

The FDA removed Wegovy, Ozempic, Mounjaro, and Zepbound from its drug shortage list for the first time in two years. The move could jeopardize the availability of cheaper, generic forms of those drugs ...

The first GLP-1 receptor agonist approved for obesity was liraglutide, marketed in the U.S. as Saxenda, in 2014. However, the ...

Lexaria Bioscience (LEXX) provides the following glucagon-like peptide-1 industry update. It is no surprise that Novo Nordisk’s ...

Shares of Hims & Hers Health Inc. rallied after hours on Monday after the wellness platform bumped its full-year sales ...

Hims & Hers has begun selling GLP-1 drugs - such as brand names like Ozempic and compounded medications that can be customized - which have been used for weight loss. In its letter to shareholders ...

Lexaria's strategy is to continue developing and optimizing our wholly-owned DehydraTECH™ drug delivery platform for application in the GLP-1 space, positioning it as a 'must-have' technology for ...